Nuvo Group Adds HealthTech Veteran Adriana Machado to Board of Directors, Strengthening Company’s Commitment to Transforming Prenatal Care
09 May 2024 - 10:30PM
Holdco Nuvo Group D.G Ltd (NASDAQ: NUVO) (“Nuvo”), a pioneer in
remote pregnancy monitoring, today announced the expansion of its
board of directors with the addition of Adriana Machado, who will
help guide Nuvo’s mission of addressing health disparities and
social determinants of care through its advanced pregnancy
monitoring technology.
“We are delighted to welcome Adriana to Nuvo’s board,” said Rice
Powell, CEO of Nuvo. “She will provide a substantial health
innovation perspective and female leadership that supports our
mission. Adriana is also a true advocate for transformation and
health equity, and we look forward to working with her to expand
our efforts and market impact.”
Machado brings three decades of experience in business
leadership, strategic planning and international relations. A
celebrated business leader in Latin America, she was the first
female CEO of GE Brazil, and is Founder of the Briyah Institute, a
Benefit Corporation (B Corp) that ignites leaders to transform
organizations by applying systems thinking to business. Ms. Machado
holds board positions with various health and civil society
organizations and, in 2013, was recognized by Forbes as one of the
10 most powerful businesswomen in Brazil.
"I am excited to join Nuvo’s board of directors at such a
pivotal time in the Company's development,” said Adriana Machado.
“I look forward to bringing my experience of the international
health innovation landscape to help the Company improve access to
care for expectant mothers across the globe.”
About Nuvo
Nuvo is leading a transformation in pregnancy care by providing
clinicians and expectant mothers with access to medically-necessary
remote pregnancy monitoring anytime, anywhere. Nuvo’s INVU™
platform is an FDA-cleared remote pregnancy monitoring and
management system. It enables the delivery of remote non-stress
tests (NSTs) and maternal and fetal heart rate monitoring, while
pioneering new data-driven personalized pathways that Nuvo believes
can improve future health outcomes. INVU is being used by leading
health providers and research institutions across the US and
Israel. Nuvo plans to continue to expand the footprint of sales in
the US and Israel and plans to introduce its INVU platform in
Europe in 2024, subject to granting of the CE mark it filed in
Europe in March 2023, to provide remote access and insights not
previously deemed possible. Nuvo is led by a diverse team of
experienced business, medical and technology leaders, united in the
mission of breaking down barriers to pregnancy care to give every
life a better beginning. For more information and complete
indications, contraindications, warnings and precautions, and
instructions for use, visit www.nuvocares.com.
Forward-Looking Statements
Certain statements contained in this press release may be
considered forward-looking statements within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995, Section 27A
of the Securities Act and Section 21E of the Exchange Act.
Forward-looking statements generally include statements that are
predictive in nature and depend upon or refer to future events or
conditions, and include words such as “may,” “will,” “should,”
“would,” “expect,” “anticipate,” “plan,” “likely,” “believe,”
“estimate,” “project,” “intend,” and other similar expressions
among others. Statements that are not historical facts are
forward-looking statements. Forward-looking statements are based on
current beliefs and assumptions that are subject to risks and
uncertainties and are not guarantees of future performance. Actual
results could differ materially from those contained in any
forward-looking statement as a result of various factors,
including, without limitation: (i) the possibility that other
anticipated benefits of the business combination will not be
realized; (ii) changes in general economic and/or industry specific
conditions; (iii) the ability of Nuvo to retain, attract and hire
key personnel; (iv) potential adverse reactions or changes to
relationships with customers, employees, suppliers or other parties
resulting from the completion of the business combination; (v)
legislative, regulatory and economic developments; (vi)
unpredictability and severity of catastrophic events, including,
but not limited to, acts of terrorism, outbreak of war or
hostilities and any epidemic, pandemic or disease outbreak
(including COVID-19), as well as management’s response to any of
the aforementioned factors; and (vii) other risk factors as
detailed in the registration statement (File No: 333-274803) on
Form F-4 filed by Nuvo with the SEC in connection with the business
combination and the prospectus/proxy statement contained therein,
as well as those risk factors detailed from time to time in Nuvo’s
reports filed with the SEC, including its Annual Report on Form
20-F and other documents filed with the SEC. The foregoing list of
important factors is not exhaustive. Except as required by
applicable law, Nuvo does not undertake any obligation to revise or
update any forward-looking statement, or to make any other
forward-looking statements, whether as a result of new information,
future events or otherwise.
CONTACTS:
Investor Relations ContactNuvo Group Ryan
Kraudelryan.kraudel@nuvocares.com
Media Relations ContactFINN Partners for Nuvo
GroupDanny Sudwartsdanny.sudwarts@finnpartners.com
+1-469-297-2515
Holdco Nuvo Group DG (NASDAQ:NUVO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Holdco Nuvo Group DG (NASDAQ:NUVO)
Historical Stock Chart
From Sep 2023 to Sep 2024